ARE

Business Context and Reporting Period

Alexandria Real Estate Equities, Inc. (ARE) is a Maryland corporation and S&P 500 company operating as a Real Estate Investment Trust (REIT). The company is the preeminent owner, operator, and developer of collaborative "Megacampus" ecosystems in AAA life science innovation clusters across North America. As of December 31, 2025, the portfolio includes 340 properties totaling approximately 39.4 million rentable square feet (RSF), with 35.9 million RSF in operating properties and 3.5 million RSF under construction. The reporting period covers the fiscal year ended December 31, 2025.

Key Financial Metrics

• Revenue: Total revenues were $3.03 billion, a decrease of 2.9% from $3.12 billion in 2024. Excluding dispositions completed after January 1, 2024, revenues would have increased by 2.3%.
• Net Income (Loss): Net loss attributable to common stockholders was $1.44 billion ($8.44 per diluted share), compared to net income of $310 million ($1.80 per diluted share) in 2024. This loss was primarily driven by $2.20 billion in real estate impairments.
• Funds From Operations (FFO): Adjusted FFO attributable to common stockholders was $1.53 billion ($9.01 per diluted share), down from $1.63 billion ($9.47 per diluted share) in 2024.
• Net Operating Income (NOI): NOI (cash basis) was $1.98 billion, a 0.1% increase from 2024. Same Property NOI decreased by 3.5% (GAAP) but increased by 0.9% (cash basis).
• Occupancy: Operating occupancy in North America was 90.9% as of December 31, 2025, down from 94.6% in 2024.
• Debt and Liquidity: Total debt was approximately $12.4 billion. The company maintained significant liquidity of $5.30 billion, including $554 million in cash and $4.65 billion in availability under its unsecured senior line of credit. Fixed-rate debt represented 97.2% of total debt.
• Dividends: The quarterly dividend was reduced to $0.72 per share for Q4 2025, a 45% reduction from the $1.32 per share declared in Q3 2025.

Material Changes Versus Prior Period

• Real Estate Impairments: The company recognized $2.20 billion in impairment charges in 2025, a significant increase from $223 million in 2024. These charges were primarily related to assets classified as held for sale and projects re-evaluated due to market conditions, including land parcels in Greater Boston, properties in San Diego, and assets in the San Francisco Bay Area.
• Dispositions: The company completed dispositions and sales of partial interests totaling $1.81 billion in 2025, exceeding the midpoint of its guidance. This included the sale of non-core assets and land to recycle capital.
• Occupancy Decline: Operating occupancy declined to 90.9% from 94.6% in the prior year, driven by an influx of new supply in key markets (Greater Boston, San Francisco, San Diego) and a moderation in tenant demand.
• Dividend Reduction: A 45% reduction in the quarterly dividend was implemented to preserve liquidity and support the 2026 capital plan.
• General and Administrative Expenses: G&A expenses decreased by 30% to $117 million, representing 5.6% of NOI, the lowest level in the past decade.

Guidance, Outlook, and Risks

• 2026 Guidance:
  • FFO per Share (Adjusted): $6.25 to $6.55 (Midpoint: $6.40).
  • Occupancy: Expected to decline to approximately 88.5% by year-end 2026.
  • Dispositions: Projected sales of $2.10 billion to $3.70 billion (Midpoint: $2.90 billion).
  • Construction Spending: Expected to range from $1.50 billion to $2.00 billion (Midpoint: $1.75 billion).
  • Debt Reduction: Targeting a reduction of approximately $1.68 billion in outstanding debt.
• Management Commentary: Management cites a "prolonged biotech bear market," reduced venture capital fundraising, and an oversupply of life science space as primary headwinds. The company is pivoting to a more disciplined capital allocation strategy, focusing on its Megacampus platform and reducing non-income-producing assets.
• Key Risks:
  • Market Supply/Demand: Significant new supply in top markets has led to elevated vacancy rates and downward pressure on rental rates.
  • Regulatory and Policy: Uncertainty regarding NIH funding, FDA staffing reductions, and potential government shutdowns poses risks to tenant R&D budgets.
  • Interest Rates: Elevated interest rates increase financing costs and may depress property valuations.
  • Tenant Credit: While 53% of rental revenue comes from investment-grade or large-cap tenants, the broader life science sector faces funding constraints.

Important Facts for Investor Verification

• Impairment Magnitude: Verify the specific assets included in the $2.20 billion impairment charge and the fair value assumptions used for assets held for sale.
• Dividend Sustainability: Assess the impact of the 45% dividend cut on the company's ability to maintain REIT status and attract income-focused investors.
• Disposition Execution: Monitor the ability to achieve the $2.90 billion midpoint disposition target in 2026 given current market liquidity and pricing pressures.
• Occupancy Trajectory: Track the projected decline to 88.5% occupancy and the associated downtime for key lease expirations in 2026 (approx. 1.2 million RSF).
• Construction Pipeline: Review the status of the 3.5 million RSF development pipeline, noting that 77% is within Megacampus ecosystems, and verify pre-leasing percentages for upcoming deliveries.